Acetato de Eslicarbazepina

Opicapona

Zamicastat

BIA 28-6156

STUDY CODE	CLINICALTRIALS.GOV	EUDRACT	PUBLICATIONS
PHASE I Studies
BIA-2093-101	NCT02171195	-	DOI:10.2165/00126839-200304050-00001
BIA-2093-102	NCT02171234	-	DOI: 10.1177/0091270004267591
BIA-2093-103	NCT02170649	-	DOI: 10.2165/00126839- 200506040-00002
BIA-2093-104	NCT01678976	-	-
BIA-2093-105	NCT02172755	-	DOI: 10.1177/0091270005279364 DOI: 10.1002/bdd.549
BIA-2093-106	NCT01878578	-	-
BIA-2093-107	NCT02172742	-	DOI: 10.1111/j.1472- 8206.2009.00691.x
BIA-2093-108	NCT02287415	-	DOI: 10.1016/j.clinthera.2010.01.014
BIA-2093-109	NCT02279667	-	DOI: 10.2165/00126839- 200506050-00001
BIA-2093-110	NCT01679002	-	DOI: 10.1111/epi.12242
BIA-2093-111	NCT02281526	-	DOI: 10.1007/s00228-007-0414-1
BIA-2093-112	NCT02281422	-	DOI 10.5414/CPP46119
BIA-2093-113	NCT01879345	2004-002994-22	-
BIA-2093-114	NCT02281448	2004-004490-28	DOI: 10.1016/j.eplepsyres.2013.02.020
BIA-2093-115	NCT02281591	2005-006016-22	-
BIA-2093-116	NCT02283788	-	DOI: 10.1177/0091270010391789
BIA-2093-117	NCT02288312	2007-000714-36	DOI: 10.2165/0126839- 200809060-00007
BIA-2093-118	NCT01879332	-	-
BIA-2093-119	NCT02283801	-	DOI: 10.1111/j.1600- 0404.2009.01233.x
BIA-2093-120	NCT02283814	-	DOI: 10.1185/03007991003740861
BIA-2093-121	NCT02283827	-	DOI: 10.1111/j.1528- 1167.2012.03519.x
BIA-2093-122	NCT02283840	-	DOI:10.4172/jbb.1000014
BIA-2093-123	NCT02284828	-	DOI: 10.1016/j.yebeh.2010.04.022
BIA-2093-124	NCT00987558	2009-012211-18	DOI: 10.1016/j.eplepsyres.2013.04.009
BIA-2093-125	NCT00971295	2007-003953-94	DOI 10.5414/CPP47255
BIA-2093-126	NCT02777671	2007-003954-27	-
BIA-2093-127	NCT00900237	2008-004800-30	DOI: 10.1111/j.1528-1167.2012.03595.x
BIA-2093-128	NCT00898560	2007-006529-28	DOI: 10.1016/j.eplepsyres.2013.02.020
BIA-2093-129	NCT02284854	2009-012550-21	DOI: 10.1111/j.1528-1167.2012.03519.x
BIA-2093-130	NCT02284880	2010-022478-15	DOI: 10.1007/s40268-013-0016-6
BIA-2093-131	NCT03116321	-	-
BIA-2093-132		2018-001484-23
PHASE II Studies
BIA-2093-201	NCT02170077	-	DOI: 10.1111/j.1528-1167.2007.00984.x
BIA-2093-202	NCT02170064	-	DOI: 10.1177/0091270008319706
BIA-2093-203	NCT01822678	2005-002131-27	DOI: 10.1016/j.jad.2014.11.013
BIA-2093-204	NCT01824602	2005-002133-13	DOI: 10.1016/j.jad.2014.11.013
BIA-2093-205	NCT01825837	2005-002134-35	DOI: 10.1016/j.jad.2014.11.013
BIA-2093-206	NCT00980746	2007-002461-12	-
BIA-2093-207	NCT00981227	2007-002473-31	-
BIA-2093-208	NCT01527513	2008-005606-39	-
BIA-2093-209	NCT01820559	2008-003736-38	-
BIA-2093-210	NCT01820585	2008-003557-32	-
BIA-2093-211	-	2012-001091-11	-
BIA-2093-211/EXT	-	2016-001072-29	-
BIA-2093-212	NCT02021461	2012-003137-41	-
BIA-2093-213	NCT06597084	2018-002747-29	-
PHASE III Studies
BIA-2093-301	NCT00957684	2004-000766-12	DOI: 10.1111/j.1528-1167.2008.01946.x DOI: 10.1111/j.1528-1167.2010.02660.x DOI: 10.1016/j.eplepsyres.2011.05.013 DOI: 10.2165/11596290-000000000-00000 DOI: 10.1111/j.1528-1167.2012.03605.x
BIA-2093-302	NCT00957047	2004-000483-27	DOI: 10.1016/j.eplepsyres.2010.01.014 DOI: 10.1016/j.eplepsyres.2012.07.014 DOI: 10.2165/11596290-000000000-00000 DOI: 10.1111/j.1528-1167.2012.03605.x
BIA-2093-303	NCT00957372	2004-001748-66	DOI: 10.1111/j.1600-0404.2009.01218.x DOI: 10.2165/11596290-000000000-00000 DOI: 10.1111/j.1528-1167.2012.03605.x
BIA-2093-304	NCT00988429	2008-002455-25	DOI: 10.1016/j.yebeh.2015.09.018 DOI: 10.1111/epi.12894
BIA-2093-305	NCT00988156	2007-001887-55	DOI: https://doi.org/10.1016/j.yebeh.2020.106962
BIA-2093-307	NCT01129960	2010-019100-23	-
BIA-2093-308	NCT01124097	2010-019101-42	-
BIA-2093-311	NCT01162460	2009-011135-13	DOI: 10.1111/epi.13993
BIA-2093-311/EXT	NCT02484001	2015-001243-36	https://doi.org/10.1111/epi.16666
PHASE IV Studies
BIA-2093-401	NCT01422720	2009-012587-14	DOI: 10.1007/s40266-018-0602-y
BIA-2093-403	NCT01532726	-	doi: 10.1111/ane.12734

STUDY CODE	CLINICALTRIALS.GOV	EUDRACT	PUBLICATIONS
PHASE I Studies
BIA-91067-101	NCT01520727	2007-004161-18	DOI: 10.1007/s40262-012-0024-7
BIA-91067-102	NCT02071810	2008-001288-12	DOI: 10.1111/bcp.12081
BIA-91067-103	NCT01515891	-	-
BIA-91067-104	NCT02071823	-	DOI: 10.1007/s40262-012-0024-7
BIA-91067-105	NCT02092168	2008-005145-35	-
BIA-91067-106	NCT02101190	2009-015899-10	DOI: 10.1007/s00228-013-1602-9
BIA-91067-107	NCT02169895	-	-
BIA-91067-108	NCT02169479	-	-
BIA-91067-109	NCT02169466	2008-003289-25	-
BIA-91067-110	NCT02169453	-	-
BIA-91067-111	NCT01532115	2010-019240-40	DOI: 10.1002/cpdd.188
BIA-91067-112	NCT01532128	2009-016073-15	-
BIA-91067-113	NCT01532141	2009-016074-32	-
BIA-91067-114	NCT01519284	2009-014549-94	-
BIA-91067-115	NCT01536366	2009-011449-24	-
BIA-91067-116	NCT02169440	2009-010765-24	-
BIA-91067-117	NCT01533077	-	-
BIA-91067-118	NCT01533116	-	DOI: 10.1111/bcp.13156
BIA-91067-119	NCT02305277	2014-000267-41	-
BIA-91067-120	NCT02305316	2013-004775-12	-
BIA-91067-121	NCT02305329	2014-000225-21	-
BIA-91067-122	NCT02169427	2011-000298-30	-
BIA-91067-123	NCT02169414	2009-018138-13	DOI: 10.1111/bcp.13156
BIA-91067-124	NCT02170376	2011-000173-31	DOI: 10.1007/s00228-014-1701-2
BIA-91067-125	NCT02305017	2013‐003871‐37	-
BIA-91067-126	NCT01520987	-	DOI: 10.1002/cpdd.213
BIA-91067-127	NCT02305030	2014-000205-13	-
BIA-91067-128	NCT03116308	2014-001626-15	-
BIA-91067-129	NCT03116295	2017-000857-37	-
BIA-91067-130	NCT03119194	2016-004454-15	-
BIA-91067-131	NCT04265027	2017-004680-13	-
BIA-91067-132	NCT03820037	2018-004748-45	-
PHASE II Studies
BIA-91067-201	NCT01568034	2008-003869-72	DOI: 10.1002/cpdd.217
BIA-91067-202	NCT01568047	2009-012897-12	DOI: 10.1111/ene.12666
PHASE III Studies
BIA-91067-301	NCT01568073	2010-021860-13	DOI: 10.1016/S1474-4422(15)00336-1 DOI: 10.3233/JPD-191593
BIA-91067-302	NCT01227655	2010-022366-27	DOI: 10.1001/jamaneurol.2016.4703 DOI: 10.3233/JPD-191593
BIA-91067-303	NCT04978597	2020-005011-52	-
PHASE IV Studies
BIA-OPC-401	NCT02847442	2016-002391-27	DOI: 10.1186/s40035-020-00187-1
BIA-91067-402	NCT03959540	-	-
BIA-91067-403	NCT04990284	2020-002754-24	-
BIA-91067-404	NCT04990284	2020-001175-32	-
BIA-91067-405	NCT04986995	2020-001176-15	-

STUDY CODE	CLINICALTRIALS.GOV	EUDRACT	PUBLICATIONS
PHASE I Studies
BIA-51058-101	NCT02151994	2010-023490-19	https://doi.org/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A3816
BIA-51058-102	NCT04991155	2015-001951-65	-
BIA-51058-104	NCT04991181	2015-002407-28	-
BIA-51058-105	NCT04991194	2015-003682-28	-
BIA-51058-106	NCT04675944	2017-000245-43	-
BIA-51058-107	NCT04991207	2015-004350-17	https://journal.chestnet.org/article/S0012-3692(20)31303-9/fulltext
BIA-51058-108	NCT04994860	2017-000224-99	https://erj.ersjournals.com/content/56/suppl_64/1458
BIA-51058-109	NCT04994119	2015-004351-49	https://journal.chestnet.org/article/S0012-3692(20)34114-3/fulltext
BIA-51058-110	-	2020‐000224‐18	-
BIA-51058-111	-	2017-002807-93	-
BIA-51058-113	-	2017-003518-23	-
BIA-51058-114	-	2017-003519-20	-
BIA-51058-115	NCT03489005	2017-001682-25	https://doi.org/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A3815
BIA-51058-116	NCT03708146	2018-000113-20	-
BIA-51058-117	-	-	-
BIA-51058-118	-	-	-
BIA-51058-119	NCT04069130	2018-003995-11	-
BIA-51058-121	-	2020‐002317‐17	-
PHASE II Studies
BIA-51058-201	NCT04316143	2018-002448-10	-
BIA-51058-202	NCT06009185	2018-002796-18	-
BIA-51058-203	-	2021-001518-12	-

STUDY CODE	CLINICALTRIALS.GOV	EUDRACT	PUBLICATIONS
PHASE I Studies
LTI-291-001	-	2017-002233-37	-
LTI-291-002	-	2017-002234-22	-
LTI-291-003	-	2017-004086-27	-
LTI-291-004	-	2018-000354-22	-
BIA-286156-105	-	2021-002546-32	-
BIA-286156-106	NCT05220072	2021-003018-38	-
BIA-286156-107	-	2021-002546-32	-
BIA-286156-109	-	2021-005896-37	-
BIA-286156-110	-	-	-
BIA-286156-111	-	2025-520754-11-00	-
BIA-286156-113	-	2025-520840-14-00	-
PHASE II Studies
BIA 28-6156	NCT05819359	2022-501783-18-00	-

Índice de Ensaios clínicos